In the ADJUNCT ONE treat‐to‐target randomized trial, around 1400 individuals with long‐lasting (undetecteble c‐peptide), uncontrolled T1D and weight excess were randomized to receive Liraglutide at three different doses (0.6, 1.2, and 1.8 mg once daily) or placebo in add‐on to background insulin treatment [77]. This evidence concerns the gene INS and type 1 diabetes mellitus.